Alzinova (ALZ) Q4 2024 earnings summary

Executive summary

• Achieved significant clinical progress with ALZ-101, completing the final patient visit in the phase 1b study; final results expected by March 2025.

• ALZ-101 demonstrated strong safety, tolerability, and immune response, supporting advancement to phase 2.

• Strategic focus on preparing for phase 2, including regulatory filings (IND, Fast Track in US, PRIME in EU) and production scale-up.

• Actively pursuing partnerships and financing, with successful rights issue raising SEK 30.5 million.

• ALZ-201 antibody project progressing toward clinical studies, broadening the pipeline.

Financial highlights

• Net sales were SEK 0 thousand for both Q4 and full year 2024 (unchanged year-over-year).

• Loss after financial items was SEK -6,563 thousand in Q4 2024 (vs. -4,731 thousand Q4 2023) and SEK -20,553 thousand for the full year (vs. -16,480 thousand in 2023).

• Earnings per share improved to SEK -0.07 in Q4 2024 (from -0.11) and SEK -0.31 for the year (from -0.41).

• Total costs for 2024 were SEK 37,193 thousand (vs. 36,396 thousand in 2023), mainly driven by R&D and preparations for phase 2.

• Cash and cash equivalents at year-end were SEK 15,496 thousand (down from SEK 22,026 thousand at end 2023).

Outlook and guidance

• Final phase 1b study results for ALZ-101 to be reported by end of March 2025.

• Phase 2 preparations on track, with regulatory submissions planned for Q3 2025.

• Ongoing business development and partnership discussions to support future clinical and commercial activities.